GNMSF (Genmab AS) Float Percentage Of Total Shares Outstanding: 98.82% (As of Jul. 04, 2026)


GNMSF Genmab AS GNMSF
93 GF Score
Price $275.00
GF Value $337.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Float Percentage Of Total Shares Outstanding?

Genmab AS GNMSF 93 Float Percentage Of Total Shares Outstanding is 98.82% as of Jul. 04, 2026. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $337.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genmab AS's float shares is 60.67 Mil. Genmab AS's total shares outstanding is 61.39 Mil. Genmab AS's float percentage of total shares outstanding is 98.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genmab AS's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genmab AS's Institutional Ownership is 0.35%.

GNMSF
93GF Score
Genmab AS GNMSF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Genmab AS's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=60.67/61.39
=98.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 98.82% mean?
Genmab AS (GNMSF) has a Float Percentage Of Total Shares Outstanding of 98.82% as of Jul. 04, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Genmab AS and its competitors.
Is Genmab AS's Float Percentage Of Total Shares Outstanding too high?
Genmab AS's current Float Percentage Of Total Shares Outstanding is 98.82%. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Genmab AS's Float Percentage Of Total Shares Outstanding of 98.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Genmab AS and its competitors. Genmab AS's current Float Percentage Of Total Shares Outstanding is 98.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $337.53, compared to a current price of $275.00 — trading 18.5% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 98.82%. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Float Percentage Of Total Shares Outstanding is 98.82% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $275.00 is trading 18.5% below its estimated GF Value™ of $337.53. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Float Percentage Of Total Shares Outstanding: 98.82%
  • GF Value™: $337.53 vs. price of $275.00 (18.5% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for GNMSF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$275.00
Price
$337.53
GF Value